Sandoz has not yet launched Zarxio (filgrastim-sndz) onto the US market but when it does so it will be the first direct competitor there for Neupogen, which had sales of $1.16 billion last year ...
Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA. Zarxio (filgrastim-sndz) is a biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback